Article Sidebar
Published:
May 11, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Entecavir/peginterferon alfa-2a combination in the treatment of two genotypes of chronic hepatitis B patients with lamivudine resistance
Abstract
Purpose: To investigate the efficacy of entecavir plus peginterferon alfa-2a in the treatment of chronic hepatitis B (CHB) patients with different hepatitis B virus (HBV) genotypes resistant to lamivudine (LAM).
Methods: 119 LAM-resistant CHB patients treated in Baoshan People's Hospital from May 2018 to May 2020 were selected. All patients received entecavir and peginterferon alfa-2a for 24 months and were scheduled for regular outpatient review and telephone follow-up. Polymerase chain reaction (PCR) was conducted to determine the HBV genotype and HBV-DNA clearance. Alanine aminotransferase (ALT) normalization rate, HBV-DNA clearance rates, and hepatitis B e-antigen (HBeAg) seroconversion rate were determined in CHB patients with different genotypes. Quality of life for all patients was assessed using SF-36 Scale.
Results: Five out of 119 patients were lost during follow-up, with a follow-up rate of 95.80 %. Two HBV genotypes were identified, of which 42 (36.8 %) were type B and 72 (63.2 %) type C. At the 6th and 12th month of follow-up, the HBV-DNA clearance rate, ALT normalization rate, and HBeAg seroconversion rate were significantly higher in CHB patients with genotype B than in patients with genotype C (p < 0.05). There were no significant differences between the three rates in the two groups at 18th and 24th month of follow-up (p > 0.05). The quality of life (QOL) of the patients differed between the two groups (p < 0.05).
Conclusion: Entecavir plus peginterferon alfa-2a are effective in treating LAM-resistant CHB patients with different genotypes. Genotype B CHB patients are more suitable for this combination protocol.
